Last updated: March 2, 2026
What is NDC 80005-0131?
NDC 80005-0131 corresponds to Eliquis (apixaban), an oral anticoagulant used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Approved by the FDA in 2012, Eliquis is marketed by Bristol-Myers Squibb and Pfizer.
Market Overview
Current Market Size and Revenue
Eliquis has maintained a strong position in the oral anticoagulant market:
| Year |
Global Sales (USD billions) |
Market Share (%) |
Leading Competitors |
| 2022 |
8.2 |
25 |
Xarelto (rivaroxaban), Pradaxa (dabigatran), Warfarin |
| 2021 |
7.8 |
24 |
- |
| 2020 |
7.0 |
22 |
- |
Source: EvaluatePharma [1].
The drug's popularity stems from its efficacy and lower bleeding risk compared to warfarin.
Market Dynamics
Key factors shaping the market include:
-
Prevalence of atrial fibrillation (AFib): Estimated at 37.5 million globally [2].
-
Age demographics: Population aging increases AFib cases.
-
Regulatory landscape: Expanded indications approved in multiple countries.
-
Competitive landscape: Eliquis faces competition primarily from:
-
Xarelto (rivaroxaban): Market leader with similar indications.
-
Pradaxa (dabigatran): Established presence, less favored now.
-
Warfarin: Older drug, but persistent due to cost.
Key Trends
-
Growing adoption in the U.S. and Europe.
-
Increased use in prophylaxis for venous thromboembolism (VTE).
-
Expansion into new indications, such as treatment of cancer-associated thrombosis.
Price Analysis and Projections
Current Pricing (U.S. Market)
-
Average wholesale price (AWP): Approximately USD 550-600 per month for a standard dose (5 mg BID).
-
Patient out-of-pocket cost: USD 10-50 with insurance, USD around USD 550 without.
Cost Factors
-
Patent status: Eliquis’s patent expires in 2031 in the U.S., with generic versions expected thereafter.
-
Reimbursement policies: CMS and private insurers negotiate prices; formulary inclusion impacts volume.
-
Manufacturing costs: Estimated at approximately USD 100-200 per month, depending on scale and supply chain efficiencies.
Price Forecast (2023-2028)
| Year |
Estimated Wholesale Price per Month |
Notes |
| 2023 |
USD 580 |
Stable, slight inflation adjustment |
| 2024 |
USD 580 |
No significant pricing change expected |
| 2025 |
USD 565 |
Minor discounts due to competitive pressures |
| 2026 |
USD 555 |
Anticipated patent expiry approaches |
| 2027 |
USD 470 |
Entry of generics expected in late 2026/2027 |
| 2028 |
USD 400 |
Generic competition dominates |
Forecast assumes no major regulatory or market disruptions.
Price Reduction Drivers
- Patent expiry stimulates generic entry.
- Increased market competition from biosimilars and generics.
- Negotiation pressures from payers.
- Regulatory reforms aimed at drug price controls.
Impact of Generic Entry
Once generics are available, prices are forecasted to decrease by approximately 70-80%, aligning with patterns seen in other anticoagulants post-patent expiration (e.g., Pradaxa).
Strategic Implications
- Expect revenue decline after 2026 due to generic competition.
- Investment focus should shift toward pipeline drugs or biosimilars.
- Companies should prepare for price erosion effects by optimizing manufacturing efficiencies.
Key Takeaways
- NDC 80005-0131 (Eliquis) commands a high current price with continued growth due to expanding indications.
- Market share is strong but faces stiff competition from Xarelto and upcoming generics.
- Price projections indicate stability until patent expiration, followed by significant declines in the late 2020s.
- The upcoming patent expiry in 2031 will largely influence the future pricing landscape.
- Payers are increasingly pushing for discounts and biosimilar adoption.
FAQs
-
When will generic versions of Eliquis become available?
Expected in late 2026 or early 2027, following patent expiry in 2031.
-
How does Eliquis compare price-wise with its competitors?
Current prices are similar to Xarelto but higher than warfarin, with generics dramatically reducing costs post-expiry.
-
What factors could accelerate patent expiry?
Patent challenges or legal disputes could lead to earlier generic entry.
-
Are there new indications that could expand Eliquis’s market?
Yes, ongoing studies are examining its use in additional thrombotic conditions, potentially expanding market size.
-
What is the primary driver of Eliquis’s revenue sustainability?
The combination of efficacy, safety profile, market penetration, and eventual patent expiration determines future revenue potential.
References
[1] EvaluatePharma. (2022). World market review of anticoagulants.
[2] Benjamin, E. J., et al. (2019). Heart disease and stroke statistics—2019 update. Circulation, 139(10), e56–e528.
